Therapeutic | Ivuxolimab |
Target | TNFRSF4 |
Heavy Chain | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIDYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARESGWYLFDYWGQGTLVTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPPTFGGGTKVEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G2 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2019 |
INN Year Recommended | 2020 |
Companies Involved | Pfizer, Dana-Farber Cancer Institute, M. D. Anderson Cancer Center, National Cancer Institute USA, University of Southern California |
Conditions Approved | na |
Conditions Active | Breast cancer, Renal cell carcinoma, Solid tumours, Acute myeloid leukaemia, Squamous cell cancer, Follicular lymphoma |
Conditions Discontinued | na |
Notes |